Drug intelligence / Profile preview

dexamethasone + prednisone + recombinant human thrombopoietin

Development stage
Unknown
Lead developer
Merck
Modality
Recombinant Proteins and Enzymes, Small Molecules
Administration
Oral, Intravenous, Subcutaneous
01

Overview

This is a combination therapy consisting of two corticosteroids (dexamethasone and prednisone) and a recombinant cytokine (recombinant human thrombopoietin, rhTPO). Dexamethasone and prednisone are synthetic glucocorticoids that suppress immune responses, reduce inflammation, and inhibit platelet destruction in immune thrombocytopenia (ITP). Recombinant human thrombopoietin is a cytokine that stimulates megakaryocyte proliferation and differentiation, thereby increasing platelet production. The combination is not standard for any specific disease but may be considered in refractory or severe cases of ITP or other forms of thrombocytopenia where both immunosuppression and enhanced platelet production are desired[2][3][7].

Other names
dexamethasone and prednisone and rhTPOdexamethasone plus prednisone plus rhTPO
02

Targets

GR (Glucocorticoid receptor)TPOR (Thrombopoietin receptor)

Beyond the preview

Go deeper on dexamethasone + prednisone + recombinant human thrombopoietin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + prednisone + recombinant human thrombopoietin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call